



## Infectious Diseases: Antibodies and Vaccines

Guest Editors:

**Dr. Huibin Lv**

Department of Biochemistry,  
University of Illinois at Urbana  
Champaign, Urbana, IL 61801,  
USA

**Dr. Yupeng Feng**

Institute for Immunity,  
Transplantation and Infection,  
Stanford University, Stanford, CA  
94305, USA

Deadline for manuscript  
submissions:

**31 December 2024**

### Message from the Guest Editors

Dear Colleagues,

Although antibodies were first discovered as tetanus and diphtheria antitoxins in 1890, it is now well known that antibodies also have an important role in controlling infectious diseases, including influenza virus and SARS-CoV-2. For example, the FDA-approved therapeutic neutralizing antibodies bamlanivimab and etesevimab are critical countermeasures for the COVID-19 pandemic. Moreover, neutralizing antibody characterization is also important for vaccine design, as exemplified by the development of several universal influenza vaccine candidates.

Therefore, antibody research not only enhances the fundamental understanding of the interaction between the immune system and pathogens, but also represents a key to improving antiviral treatment in humans. In this Special Issue, we focus on neutralizing antibody screening, cross-reactive antibody epitope mapping and structure-based vaccine design.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)